FUJIFILM Diosynth Biotechnologies

Jun 11, 2024 | bioprocessonline.com | Gunjan Bagla |Mel Palmer |Lars Petersen |FUJIFILM Diosynth Biotechnologies

Webinar: Navigating your Holistic Approach to Container Closure Integrity for Biologic Drug ProductsJoin us on June 12th to see the benefit of a comprehensive approach to CCI tailored for several biologic drug products -mAbs and complex modalities such as fusion proteins or bioconjugates as well as learn the regulatory expectations and industry best practices on CCI! We’ll discuss timely initiate activities of more complex cases such as combinations products. Click here to learn more.

Nov 21, 2023 | outsourcedpharma.com | Louis Garguilo |Eric Gudorf |Erika Morris |FUJIFILM Diosynth Biotechnologies

Join The Drug Delivery Leader CommunityWe’re excited to introduce a new online community focused on all aspects of drug formulation and delivery system development! Drug Delivery Leader will help you stay on top of global regulations, discover new technologies and design trends, shorten development times, and much more. Sign up for the free Drug Delivery Leader newsletter, delivered to your inbox weekly.

Nov 15, 2023 | bioprocessonline.com | John F Cipollo |Nick Hutchinson |FUJIFILM Diosynth Biotechnologies |Alice Levis

Interested in bringing your monoclonal antibody from transfection to GMP drug substance in nine months? Join us for a panel discussion to explore our Accelerated mAb Development Program. Meet our experts who have developed our phase-appropriate and cost-effective program, which is scalable and integrates strategies for risk mitigation. Watch now. The lightning-fast rise of mRNA raised the need for manufacturing standards and consensus on product quality attributes and test methods.

Oct 12, 2023 | outsourcedpharma.com | Paul Cummings |Tim Sandle |AGC Biologics |FUJIFILM Diosynth Biotechnologies |Louis Garguilo

Webinar: Bridging The Gap Between mAbs And Next-Generation TherapeuticsThe inherent complexity of certain molecules, such as bispecific antibodies and Fc-fusion proteins, can impose additional challenges during development when compared to mAbs.